GlassScriptPhysician profile
Yecena Castaneda
NPI 1891205530
$3,190.19
in general payments reported to CMS, 2019-2025
9 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $281 · 2023: $369 · 2024: $1,895 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423 · Travel and Lodging: $1,171 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.10 |
| Travel and Lodging | $1,171.37 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,817.69 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $616.32 | 2023-2025 | Gemtesa |
| Mission Pharmacal Company | $332.51 | 2021-2024 | Uribel, Uribel Tabs |
| Astellas Pharma US INC | $244.69 | 2021-2023 | |
| Valencia Technologies Corporation | $68.08 | 2025 | Ecoin Device Kit |
| Medtronic, INC. | $57.69 | 2023-2025 | Interstim, Altaviva |
| Bayer Healthcare Pharmaceuticals INC. | $18.99 | 2022 | |
| Coloplast Corp | $18.08 | 2023 | Speedicath |
| Boston Scientific Corporation | $16.14 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yecena Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.